Effect of vildagliptin on the levels of HOMA-IR, hs-CRP, TNF-α and IL-6 in patients with type 2 diabetes mellitus
-
Received Date:
2018-06-29
Accepted Date:
2019-05-01
-
Abstract
ObjectiveTo explore the effects of vildagliptin on the levels of insulin resistance index(HOMA-IR), high sensitive C reactive protein(hs-CRP), tumor necrosis factor alpha(TNF-α) and interleukin -6(IL-6) in patients with type 2 diabetes mellitus.MethodsNinety-six patients with type 2 diabetes mellitus were randomly divided into the control group and observation group(48 cases in each group).The control group was treated with metformin hydrochloride tablets, and the observation group was treated with vildagliptin based on the control group.The levels of fasting blood glucose(FBG), 2 h postprandial blood glucose(2hPBG), glycosylated hemoglobin(HbA1c), fasting insulin (Fins) and HOMA-IR were detected in two groups.ResultsThe differences of the levels of FBG, 2hPBG, HbA1c, Fins and HOMA-IR between two groups before treatment were not statistically significant(P>0.05).After treatment, these indictors in two groups decreased, the levels of FBG, 2hPBG and HbA1c in control group decreased compared with before treatment(P < 0.01), the levels of FBG, 2hPBG, HbA1c, Fins and HOMR-IR in observation group decreased compared with before treatment, and these indictors in observation group were lower than those in control group(P < 0.01).The differences of the levels of hs-CRP, IL-6and TNF-α between two groups before treatment were not statistically significant(P>0.05).After treatment, the levels of IL-6 and TNF-α in control group significantly decreased compared with before treatment(P < 0.01), the levels of hs-CRP, IL-6 and TNF-α in observation group significantly decreased compared with before treatment, and these indictors in observation group were lower than those in control group(P < 0.01).ConclusionsVildaglipti can improve the insulin resistance, and significantly reduce the level of inflammatory factors in type 2 diabetic patients, which has high clinical value.
-
-
References
[1]
|
侯清涛, 李芸, 李舍予.全球糖尿病疾病负担现状[J].中国糖尿病杂志, 2016, 24(1):92. doi: 10.3969/j.issn.1006-6187.2016.01.023 |
[2]
|
何春秀, 郝桂荣, 张会君, 等.老年2型糖尿病患者医学应对方式及影响因素研究[J].中国全科医学, 2015, 15(5):525. doi: 10.3969/j.issn.1007-9572.2015.05.010 |
[3]
|
张霞.2型糖尿病的临床发病机制分析[J].齐齐哈尔医学院学报, 2013, 34(18):2673. doi: 10.3969/j.issn.1002-1256.2013.18.013 |
[4]
|
张黎明, 高凌.炎症细胞因子在2型糖尿病发病机制中的研究进展[J].重庆医学, 2016, 45(8):1113. doi: 10.3969/j.issn.1671-8348.2016.08.038 |
[5]
|
刘琼, 何翠英, 卫家芬.DPP-4抑制剂治疗2型糖尿病的研究进展及临床应用[J].实用药物与临床, 2015, 18(7):856. |
[6]
|
廖涌.中国糖尿病的流行病学现状及展望[J].重庆医科大学学报, 2015, 40(7):1042. |
[7]
|
DEACON CF, HOLST JJ.Dipptidyl peptidase 4 inhibitors:a promising new therapeutic approach for the management of type 2 diabetes[J].Int J biochem Cell Bio, 2006, 38(5/6):831. |
[8]
|
AMORI RE, LAU J, PITTAS AG.Efficacy and safety of incretin therapy in type 2 diabetes:systematic review and meta-analysis[J].JAMA, 2007, 298:194. doi: 10.1001/jama.298.2.194 |
[9]
|
ILKOVA H, GLASER B, TUNÇKALE A, et al.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment[J].Diabetes Care, 1997, 20(9):1353. doi: 10.2337/diacare.20.9.1353 |
[10]
|
HOTAMISLIGIL GS.Inflammatory pathways and insulin action[J].Int J Obes Relat Metab Disord, 2003, 27(Suppl)3:S53.[1] HEIDARI J, MIERSWA T, HASENBRING M, et al.Low back pain in athletes and non-athletes:a group comparison of basic pain parameters and impact on sports activity[J].Sport Sci Health, 2016, 12(3):1. doi: 10.1038/sj.ijo.0802502 |
-
-
Proportional views
-